Investigating how a specific protein influences cancer-related inflammation and tumor growth in breast cancer.
Official title: p27pTpT drives cancer-promoting inflammation and shapes the tumor microenvironment (TME) toward a more tumor-permissive state in vivo
Funded at Georgetown University · NIH-11233640 · Data updated 2026-11-12
This study is looking at a protein called p27pTpT to see how it helps breast cancer grow and resist treatment, with the hope of finding new ways to improve care for patients battling this disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgetown University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project start | November 19, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $3,000 |
| NIH project number | 3F99CA284295-02S1 |
| Project ID | NIH-11233640 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with breast cancer, particularly those experiencing treatment resistance.
✕Less likely to help
Patients with non-breast cancer types or those who are not experiencing therapy resistance may not benefit from this research.
What this research studies
This research focuses on understanding the role of a protein called p27pTpT in breast cancer, particularly how it contributes to therapy resistance and alters the tumor microenvironment to help tumors evade the immune system. The study examines the molecular mechanisms by which p27pTpT promotes the growth of cancer stem cells and drives inflammation that supports tumor development. By using advanced techniques like ChIP-seq and RNA-seq, the researchers aim to identify how p27pTpT interacts with other proteins to influence cancer progression. This work could lead to new insights into potential therapeutic targets for improving treatment outcomes in breast cancer patients.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for overcoming therapy resistance in breast cancer, potentially improving survival rates.
How similar studies have gone: Other research has shown promising results in targeting similar molecular pathways in cancer, suggesting that this approach could be effective.
Where this research is happening
-
Georgetown University
Washington, United States Active
Researchers
- Principal investigator: Razavipour, Seyedehfatemeh — Georgetown University
- Study coordinator: Razavipour, Seyedehfatemeh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.